[Effect of hypotensive therapy on metalloproteinase activity of the blood in patients with arterial hypertension].

Abstract

Aim of the study--investigation of dynamics of levels of serum markers of myocardial fibrosis matrix metalloproteinase-1 (MMP-1), tissue inhibitor of matrix metalloproteinase-1 (TIMP-1)--at the background of 3 months hypotensive therapy in 39 patients with arterial hypertension and paroxysmal form of atrial fibrillation. Twenty patients received sotalol, 19--retard form of verapamil. After 3 months of hypotensive therapy in all patients and separately in groups of patients receiving sotalol and verapamil no significant changes of MMP-1 and TIMP-1 occurred. However in patients with most pronounced hypotensive effect according to 24-hour blood pressure monitoring significant elevation of MMP-1 and lowering of TIMP-1 levels took place. This was associated with improvement of ventricular diastolic function. In most patients longer period of therapy (more than 3 months) is required for achievement of regression of damage to the heart.

• Authors: N A Mazur, F M Khezheva
• Journal: Kardiologiia (Kardiologiia) Vol. 49 Issue 2 Pg. 27-31 ( 2009) ISSN: 0022-9040 [Print] Russia (Federation)
• PMID: 19254213 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Adrenergic beta-Antagonists
• Tissue Inhibitor of Metalloproteinase-1
• Vasodilator Agents
• Sotalol
• Verapamil
• Matrix Metalloproteinase 1

Topics

• Adrenergic beta-Antagonists (therapeutic use)
• Adult
• Aged
• Blood Pressure (drug effects, physiology)
• Blood Pressure Monitoring, Ambulatory
• Enzyme-Linked Immunosorbent Assay
• Female
• Fibrosis (enzymology, etiology, pathology)
• Follow-Up Studies
• Heart Diseases (enzymology, etiology, pathology)
• Humans
• Hypertension (complications, drug therapy, enzymology)
• Male
• Matrix Metalloproteinase 1 (blood, drug effects)
• Middle Aged
• Myocardium (pathology)
• Sotalol (therapeutic use)
• Tissue Inhibitor of Metalloproteinase-1 (blood, drug effects)
• Treatment Outcome
• Vasodilator Agents (therapeutic use)
• Verapamil (therapeutic use)